

DAFTAR PUSTAKA

- Aksoy Poyraz, C., Turan, Ş., Demirel, Ö. F., Usta Sağlam, N. G., Yıldız, N., & Duran, A. (2015). Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: Case series. *Therapeutic Advances in Psychopharmacology*, 5(4), 237–242. <https://doi.org/10.1177/2045125315584871>
- Amalia, I., & Hermawati, E. (2022). Hubungan karakteristik pasien skizofrenia terhadap tingkat kekambuhan di Rumah Sakit Jiwa Daerah Sungai Bangkong Pontianak. *Jurnal Cerebellum*, 8(2), 1–6. <https://doi.org/10.26418/jc.v>
- Antari, N. P. G., & Suariyani, N. L. P. (2021). Faktor-Faktor Yang Berhubungan Dengan Kekambuhan Pada Pasien Skizofrenia Di Kabupaten Badung. *Archive of Community Health*, 8(2), 304. <https://doi.org/10.24843/ach.2021.v08.i02.p08>
- Arayeshgari M, Roshanaei G, Ghaleiha A, Poorolajal J, Tapak L. (2022). Investigating factors associated with the number of rehospitalizations among patients with schizophrenia disorder using penalized count regression models. *BMC Med Res Methodol*. Jun 15;22(1):170. doi: [10.1186/s12874-022-01648-z](https://doi.org/10.1186/s12874-022-01648-z)
- Aryani, F., & Sari, O. (2016). Gambaran Pola Penggunaan Antipsikotik pada Pasien Skizofrenia di Ruang Rawat Inap Rumah Sakit Jiwa. *Jurnal Manajemen Dan Pelayanan Farmasi*, 6(1), 35–40.
- Avcı, E. (2021). Using Count Regression Models to Determine the Factors which Effects the Hospitalization Number of People with Schizophrenia. *Journal of Data Science*, 16(3), 511–530. [https://doi.org/10.6339/jds.201807_16\(3\).0004](https://doi.org/10.6339/jds.201807_16(3).0004)
- Azmi, A. N., & Desrini, S. (2016). A cross sectional study of trihexyphenidyl utilization on patient receiving antipsychotic therapy. *Jurnal Kedokteran Dan Kesehatan Indonesia*, 7(3), 102–108. <https://doi.org/10.20885/jkki.vol7.iss3.art5>
- Baker, J., & Aebi, C. (2017). Comparison of readmission data between different categories of antipsychotic drugs at a state psychiatric hospital in Oregon. *Mental Health Clinician*, 7(3), 124–130. <https://doi.org/10.9740/mhc.2017.05.124>
- Blessing, I. O., Iyalomhe, G. B. S., George, E. O., Okojie, F. O. & Solomon, A. O. (2013). Effect of chlorpromazine and haloperidol combination on lipid profile in Nigeria schizophrenic patients. *International Journal of Medical and Pharmaceutical Sciences*, 3(12), 11–20
- BNF. (2018). *Medicines Information Services*. www.sps.nhs.uk/ukdilas
- Boaz, T. L., Becker, M. A., Andel, R., Van Dorn, R. A., Choi, J., & Sikirica, M. (2013). Risk factors for early readmission to acute care for persons with Schizophrenia

taking antipsychotic medications. *Psychiatric Services*, 64(12), 1225–1229.
<https://doi.org/10.1176/appi.ps.003382012>

Caffrey, A. R., & Borrelli, E. P. (2020). The art and science of drug titration. In *Therapeutic Advances in Drug Safety* (Vol. 11). SAGE Publications Ltd.
<https://doi.org/10.1177/2042098620958910>

Chan, S. K. W., Suen, Y. N., Yan, W. C., Lam, C., Chui, E., Hui, C. L. M., Chang, W. C., Lee, E. H. M., Chen, E. Y. H., Honer, W. G., & Takeuchi, H. (2023). Clozapine dosing patterns and clinical outcomes in patients with treatment resistant schizophrenia. *European Neuropsychopharmacology*, 75, 67–79.
<https://doi.org/10.1016/j.euroneuro.2023.07.007>

Chisholm-Burns, M.A., Schwinghammer T., Malone P.M., Kolesar J.M., Lee K.C., Bookstaver P.B. (2019). *Pharmacotherapy: Principles & Practice Fifth Edition*. New York: McGraw-Hill.

Chokhawala, K., & Stevens, L. (2023). *Antipsychotic Medications Continuing Education Activity*. StatePearls Publishing.
<https://www.ncbi.nlm.nih.gov/books/NBK519503/>

Correll, C. U., & Howes, O. D. (2021). Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options. *Journal of Clinical Psychiatry*, 82(5).
<https://doi.org/10.4088/JCP.MY20096AH1C>

Correll, C. U., Agid, O., Crespo-Facorro, B., de Bartolomeis, A., Fagiolini, A., Seppälä, N., & Howes, O. D. (2022). A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. *CNS Drugs*, 36(7), 659–679. <https://doi.org/10.1007/s40263-022-00932-2>

Cristarella, T., Castillon, G., Nepveu, J. F., & Moride, Y. (2022). Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta-analysis of observational studies. In *Pharmacology Research and Perspectives* (Vol. 10, Issue 1). John Wiley and Sons Inc. <https://doi.org/10.1002/prp2.915>

Dewi Yunitasari, F., & Maidatuz Zulfa, I. (2018). Hospitalisasi Pasien Skizofrenia di Rumah Sakit Jiwa Menur Surabaya. *Journal of Pharmacy and Science*, 3(2).

M. Lynn Crismon, Tami R. Argo, and Peter F. Buckley (Ed.). (2020). *Pharmacotherapy: A pathophysiologic approach* (Eleventh edition). McGraw Hill Medical.

Ernest, D., Olga Vuksic, R., Ashley Shepard-Smith, Ms., Emily Webb, R., & Reg, O. (2017). *Schizophrenia An information guide revised edition*. Library and Archives Cataloguing.

- Fatani, B. Z., Aldawod, R. A., & Alhawaj, F. A. (2017). Schizophrenia : Etiology, Pathophysiology and Management : A Review. *The Egyptian Journal of Hospital Medicine*, 69(6), 2640–2646. <https://doi.org/10.12816/0042241>
- Flanagan, R. J., Lally, J., Gee, S., Lyon, R., & Every-Palmer, S. (2020). Clozapine in the treatment of refractory schizophrenia: A practical guide for healthcare professionals. *British Medical Bulletin*, 135(1), 73–89. <https://doi.org/10.1093/bmb/ldaa024>
- Foster, A., Buckley, P., Lauriello, J., Looney, S., & Schooler, N. (2017). Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial. *Journal of clinical psychopharmacology*, 37(5), 595–599. <https://doi.org/10.1097/JCP.0000000000000766>
- Goff DC. (2019). Can adjunctive pharmacotherapy reduce hospitalization in schizophrenia? Insights from administrative databases. *JAMA Psychiatry*. [Epub ahead of print]
- Guo, J., Lv, X., Liu, Y., Kong, L., Qu, H., & Yue, W. (2023). Influencing factors of medication adherence in schizophrenic patients: a meta-analysis. *Schizophrenia*, 9(1), 23–25. <https://doi.org/10.1038/s41537-023-00356-x>
- Hafifah, A., Puspitasari, I. M., & Sinuraya, R. K. (2018). Farmakoterapi dan Rehabilitasi Psikososial pada Skizofrenia. *Farmaka*, 16(2), 210–232.
- Handayani, L., Febriani, F., Rahmadanni, A., & Saufi, A. (2017). Faktor Risiko Kejadian Skizofrenia Di Rumah Sakit Jiwa Grhasia Daerah Istimewa Yogyakarta (Diy). *Humanitas*, 13(2), 135. <https://doi.org/10.26555/humanitas.v13i2.6069>
- Hany, M., Baryiah, ;, Yusra Azhar, R. ;, & Chapman, J. (2023). *Schizophrenia*. StatePearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK539864/>
- Heald, A., Pendlebury, J., Anderson, S., Narayan, V., Guy, M., Gibson, M., Haddad, P., & Livingston, M. (2017). Lifestyle factors and the metabolic syndrome in Schizophrenia: A cross-sectional study. *Annals of General Psychiatry*, 16(1), 12. <https://doi.org/10.1186/s12991-017-0134-6>
- Heslin, K. C., & Weiss, A. J. (2015). *Hospital Readmissions Involving Psychiatric Disorders*, 2012. <https://hcup-us.ahrq.gov/reports/statbriefs/sb189-Hospital-Readmissions-Psychiatric-Disorders-2012.jsp>
- Hosakova, J. L. (2016). The complex etiology of schizophrenia-general state of the art. In *Neuroendocrinology Letters* (Vol. 36, Issue 7). nel.edu. www.nel.edu
- Indriani, A., Ardiningrum, W., & Febrianti, Y. (2020). Studi Penggunaan Kombinasi Antipsikotik pada Pasien Skizofrenia di Rumah Sakit Yogyakarta. *Majalah*

Farmasetika., 4(Suppl 1), 201–211.
<https://doi.org/10.24198/mfarmasetika.v4i0.25882>

Istichomah, & R, F. (2019). the Effectiveness of Family Knowledge About Schizophrenia Toward Frequency of Recurrence of Schizophrenic Family Members At Poly Mental Grhasia Mental Hospital D. I. Yogyakarta. *Jurnal Kesehatan Samora Ilmu*, 10(2), 1689–1699. www.journal.uta45jakarta.ac.id di akses pada tanggal 6 Desember 2023

Jeyagurunathan, A., Vaingankar, J. A., Abdin, E., Sambasivam, R., Seow, E., Pang, S., Picco, L., Chong, S. A., & Subramaniam, M. (2017). Gender differences in positive mental health among individuals with schizophrenia. *Comprehensive psychiatry*, 74, 88–95. <https://doi.org/10.1016/j.comppsy.2017.01.005>

John Lisa. (2019). *SESLHD Procedur Cover Sheet Compliance With This Document Is Mandatory*.

Josiassen, R. C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W. W., & Shaughnessy, R. A. (2005). Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial. *American Journal of Psychiatry*, 162(1), 130–136. <https://doi.org/10.1176/appi.ajp.162.1.130>

Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., Van Os, J., & Insel, T. R. (2015). Schizophrenia. *Nature Reviews Disease Primers*, 1. <https://doi.org/10.1038/nrdp.2015.67>

Keating, D., McWilliams, S., Schneider, I., Hynes, C., Cousins, G., Strawbridge, J., & Clarke, M. (2017). Pharmacological guidelines for schizophrenia: A systematic review and comparison of recommendations for the first episode. *BMJ Open*, 7(1). <https://doi.org/10.1136/bmjopen-2016-013881>

Kementerian Kesehatan RI. (2013). Riset Kesehatan Dasar 2013. Kementerian Kesehatan RI. 225.

Kementerian Kesehatan RI. (2015). Keputusan Menteri Kesehatan RI Nomor HK.02.02/MENKES/73/2015 tentang Pedoman Nasional Pelayanan Kedokteran Jiwa. Kementerian Kesehatan RI. 24-30.

Kementerian Kesehatan RI. (2018). Riset Kesehatan Dasar 2018. Kementerian Kesehatan RI. 225.

Kesserwani, J., Kadra, G., Downs, J., Shetty, H., MacCabe, J. H., Taylor, D., Stewart, R., Chang, C. K., & Hayes, R. D. (2019). Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine. *Journal of*

Psychopharmacology, 33(4), 449–458.
<https://doi.org/10.1177/0269881118817387>

Khan, A. H., & Zaidi, S. (2017). Clozapine: Improvement of Negative Symptoms of Schizophrenia. *Cureus*. <https://doi.org/10.7759/cureus.1973>

Lähteenpuo, M., & Tiihonen, J. (2021). Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. In *Drugs* (Vol. 81, Issue 11, pp. 1273–1284). Adis. <https://doi.org/10.1007/s40265-021-01556-4>

Legge, S. E., Santoro, M. L., Periyasamy, S., Okewole, A., Arsalan, A., & Kowalec, K. (2021). Genetic architecture of schizophrenia: A review of major advancements. In *Psychological Medicine* (Vol. 51, Issue 13, pp. 2168–2177). Cambridge University Press. <https://doi.org/10.1017/S0033291720005334>

Li, R., Ma, X., Wang, G., Yang, J., & Wang, C. (2016). Why sex differences in schizophrenia?. *Journal of translational neuroscience*, 1(1), 37–42.

Lin, C. H., Lin, S. C., Chen, M. C., & Wang, S. Y. (2006). Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone. *Journal of the Chinese Medical Association*, 69(6), 264–269. [https://doi.org/10.1016/S1726-4901\(09\)70254-0](https://doi.org/10.1016/S1726-4901(09)70254-0)

Masand, P. S. (2005). A review of pharmacologic strategies for switching to atypical antipsychotics. *Primary Care Companion to the Journal of Clinical Psychiatry*, 7(3), 121–129. <https://doi.org/10.4088/PCC.v07n0309>

Maudy, N., Hasan, A. H., & Wati, Y. R. (2020). Perbandingan Frekuensi Rawat Inap Penderita Skizofrenia berdasarkan Jenis Obat Antipsikotik yang Diminum di RSJ Provinsi Jawa barat. *Universitas Islam Bandung*, 488–491. <https://karyailmiah.unisba.ac.id/index.php/dokter/article/view/21263>

Nucifora, F. C., Mihaljevic, M., Lee, B. J., & Sawa, A. (2017). Clozapine as a Model for Antipsychotic Development. In *Neurotherapeutics* (Vol. 14, Issue 3, pp. 750–761). Springer New York LLC. <https://doi.org/10.1007/s13311-017-0552-9>

Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N., & Sawa, A. (2019). Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. In *Neurobiology of Disease* (Vol. 131). Academic Press Inc. <https://doi.org/10.1016/j.nbd.2018.08.016>

Olivares, J. M., Sermon, J., Hemels, M., & Schreiner, A. (2013). Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. *Annals of general psychiatry*, 12(1), 32. <https://doi.org/10.1186/1744-859X-12-32>

- Ortiz-Orendain, J., Castiello-de Obeso, S., Colunga-Lozano, L. E., Hu, Y., Maayan, N., & Adams, C. E. (2017). Antipsychotic combinations for schizophrenia. In *Cochrane Database of Systematic Reviews* (Vol. 2017, Issue 6). John Wiley and Sons Ltd. <https://doi.org/10.1002/14651858.CD009005>
- Patel K., R., P. R. J. C. (2014). *Schizophrenia: Overview and Treatment Options*. *P & T : a peer-reviewed journal for formulary management*, 39(9), 638–645. <https://pubmed.ncbi.nlm.nih.gov/25210417/>
- Pebrianti, D. K. (2021). Penyuluhan Kesehatan tentang Faktor Penyebab Kekambuhan Pasien Skizofrenia. *Jurnal Abdimas Kesehatan (JAK)*, 3(3), 235. <https://doi.org/10.36565/jak.v3i3.160>
- Pratiwi SH, Marchira CR, Hendartini J. (2017). Faktor-faktor yang Mempengaruhi Rawat Inap Ulang Pasien Skizofrenia pada Era Jaminan Kesehatan Nasional Di Rumah Sakit Jiwa Grhasia Pemda DIY. *Jurnal Kebijakan Kesehatan Indonesia*, 06(1):20-8. <https://doi.org/10.22146/jkki.v6i1.29005>
- Rezki, D., Dan, A., & Anwar, Z. (2013). *Relaps Pada Pasien Skizofrenia*. In *Jurnal Ilmiah Psikologi Terapan* (Vol. 01, Issue 01). <https://doi.org/10.22219/jipt.v1i1.1357>
- Riduwan dan Akdon. (2010). *Rumus dan Data dalam Analisis Data Statistika*. Bandung: Alfabeta.
- Risdianto Eka Putra I. P., M. (2023). *Neurobiologi dan Tatalaksana Gangguan Kognitif pada Skizofrenia*. <https://jurnalcentekia.id/index.php/jhpp/>
- Rissa, M. M., Darmawan, E., & Siwinarni, A. (2020). Profil Penggunaan Obat Kombinasi Risperidone-Clozapine dan Risperidone dengan Antipsikotik Lain pada Pasien Gangguan Mental Psikotik di Rumah Sakit Jiwa Grhasia Yogyakarta. *Jurnal Surya Medika*, 5(2), 131–138. <https://doi.org/10.33084/jsm.v5i2.1320>
- Roerig J. L. (2019). Clozapine augmentation strategies. *Mental Health Clinician*, 9(6), 336-48. <https://doi.org/10.9740/mhc.2019.11.336>.
- Rubio, J. M., & Kane, J. M. (2022). The pharmacological treatment of schizophrenia: How far have we come? *Psychiatry and Clinical Neuroscience Reports*, 1(2). <https://doi.org/10.1002/pcn5.13>
- Rusdi, N. K., Nugroho, A., & Saputra, A. (2015). Drug Related Problems Antipsikotik pada Pasien Skizofrenia Paranoid Akut di RS Jiwa X Jakarta. *Farmasains*, 2(6), 275–280.
- Saharuddin, Ikawati, Z., & Kristanto. (2021). Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien Schizophrenia di RSJ Dr. Ernaldi Bahar Palembang. *Majalah*

Farmaseutik, 17(2), 206–216.

- Sandy. 2020. *Clozapine*. NeuRA Library. <https://library.neura.edu.au/index.html>
- Saputra, T. A. (2014). Paranoid Types of Schizophrenia. *J Agromed Unilla*, 1(1), 42–48. <https://joke.kedokteran.unila.ac.id/index.php/agro/article/download/1334/pdf>
- Sato, A., Moriyama, T., Watanabe, N., Maruo, K., & Furukawa, T. A. (2023). Development and validation of a prediction model for rehospitalization among people with schizophrenia discharged from acute inpatient care. *Frontiers in Psychiatry*, 14. <https://doi.org/10.3389/fpsyt.2023.1242918>
- Subramanian, S., Völm, B. A., & Huband, N. (2017). Clozapine dose for schizophrenia. *Cochrane Database of Systematic Reviews*, 2017(6). <https://doi.org/10.1002/14651858.CD009555.pub2>
- Sudarmono, Nur Afni, Mohammad Andri, R. (2018). *FAKTOR RISIKO KEJADIAN SKIZOFRENIA DI RUMAH SAKIT MADANI PALU. Vol 1 No 1*, 540–550. <https://doi.org/https://doi.org/10.56338/jks.v1i1.387>
- Sugai, T., Suzuki, Y., Yamazaki, M., Shimoda, K., Mori, T., Ozeki, Y., Matsuda, H., Sugawara, N., Yasui-Furukori, N., Minami, Y., Okamoto, K., Sagae, T., & Someya, T. (2016). High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: A nationwide survey. *PLoS ONE*, 11(11), 1–12. <https://doi.org/10.1371/journal.pone.0166429>
- Stuart, G. W. (2013). *Principles and Practice of Psychiatric Nursing* (10th ed). St Louis, Missouri: Elsevier Mosby
- Tiihonen, J., Taipale, H., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tanskanen, A. (2019). Association of Antipsychotic Polypharmacy vs Monotherapy with Psychiatric Rehospitalization among Adults with Schizophrenia. *JAMA Psychiatry*, 76(5), 499–507. <https://doi.org/10.1001/jamapsychiatry.2018.4320>
- Tsuang. (2011). *British Journal of Psychiatry*, Dampak Pribadi Schizopfreina di Eropa, 2(69), pp. 125-132.
- Vallianatou, K. (2016). *Antipsychotics*. In *Elsevier Ltd* (Vol. 44, Issue 12, pp. 748–752). <https://www.sciencedirect.com/science/article/pii/S1357303916302018>
- Veeneman, R. R., Vermeulen, J. M., Abdellaoui, A., Sanderson, E., Wootton, R. E., Tadros, R., Bezzina, C. R., Denys, D., Munafò, M. R., Verweij, K. J. H., & Treur, J. L. (2022). Exploring the Relationship Between Schizophrenia and Cardiovascular Disease: A Genetic Correlation and Multivariable Mendelian Randomization Study. *Schizophrenia bulletin*, 48(2), 463–473. <https://doi.org/10.1093/schbul/sbab132>

- Volkan, K. (2020). Schizophrenia: Epidemiology, Causes, Neurobiology, Pathophysiology, and Treatment. *Journal of Health and Medical Sciences*, 3(4). <https://doi.org/10.31014/aior.1994.03.04.143>
- Wagner, E., Siafis, S., Fernando, P., Falkai, P., Honer, W. G., Röhl, A., Siskind, D., Leucht, S., & Hasan, A. (2021). Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. In *Translational Psychiatry* (Vol. 11, Issue 1). Springer Nature. <https://doi.org/10.1038/s41398-021-01613-2>
- Ward, A., Ishak, K., Proskorovsky, I., Bsc2, ;, & Caro, J. (2006). Compliance with Refilling Prescriptions for Atypical Antipsychotic Agents and Its Association with the Risks for Hospitalization, Suicide, and Death in Patients with Schizophrenia in Quebec and Saskatchewan: A Retrospective Database Study. In *Clin Ther* (Vol. 28).
- Wardani, I. Y., & Dewi, F. A. (2018). Kualitas Hidup Pasien Skizofrenia Dipersepsikan Melalui Stigma Diri. *Jurnal Keperawatan Indonesia*, 21(1), 17–26. <https://doi.org/10.7454/jki.v21i1.485>
- WHO. (2022). Schizophrenia. Retrieved September 13, 2023, from <https://www.who.int/news-room/fact-sheets/detail/schizophrenia>
- Yulianty M. D., C. N. & M. S. V. (2018). Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. *Jurnal Sains Farmasi & Klinis*, 3(2).
- Zahnia, S., & Wulan Sumekar, D. (2016). Kajian Epidemiologis Skizofrenia. *Majority*, 5(5), 160–166. <http://joke.kedokteran.unila.ac.id/index.php/majority/article/view/904/812>
- Zhan, N., Sham, P. C., So, H. C., & Lui, S. S. Y. (2023). The genetic basis of onset age in schizophrenia: evidence and models. *Frontiers in Genetics*, 14(June), 1–10. <https://doi.org/10.3389/fgene.2023.1163361>